UNSPSC 51391730: Pirbuterol

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG645J8RVW, chemically known as ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)- but generally known as pirbuterol, which bears US NIH Compound Identifier 4845. European Medicines Agency schedules Pirbuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09900MIG.

UNSPSC 51391730 Pirbuterol is a Commodity code that in recent state and local procurement activity represents pharmaceutical and emergency medical supply procurement more broadly, though the single recent opportunity on file shows a mismatch with the code's nominal scope. Seminole County, Florida posted an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, a procurement framed as supporting community health initiatives with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option and requires vendors to meet drug-free workplace certification, E-Verify compliance, and specific insurance coverages including workers' compensation, commercial general liability, and professional liability. Vendors submit bids electronically through the county's e-Procurement Portal with all shipping and delivery costs included in the proposal. The opportunity indicates potential FEMA funding with associated federal compliance requirements. The single recent opportunity limits visibility into the full range of work actually being pursued under this code or the distribution of issuing bodies engaging it.

The only recent opportunity on file is the Seminole County IFB with a due date of July 26, 2023, representing activity in Florida. The mismatch between the code's nominal focus on pirbuterol (a bronchodilator) and the actual procurement of naloxone and drug deactivation systems suggests either a coding error in the opportunity record or a broader misconfiguration of the code's application in state and local procurement systems. Without additional recent opportunities across other jurisdictions, geographic spread and issuing-body concentration cannot be assessed. Business development professionals should verify the code's actual use in their target markets before relying on this classification for opportunity identification.